Results 201 to 210 of about 71,439 (210)

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

European Journal of Cancer, 2009
Fabienne Thomas, Philippe Rochaix, Melanie L White-Koning   +2 more
exaly  

Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib

Acta Pharmacologica Sinica, 2011
Zhong-Ze Fang, Wei Li
exaly  

Erlotinib

Reactions Weekly
openaire   +1 more source

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Journal of Clinical Pharmacology, 2006
exaly  

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

Drugs, 2012
exaly  

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

Cancer Chemotherapy and Pharmacology, 2014
exaly  

Erlotinib and pantoprazole: a relevant interaction or not?

British Journal of Clinical Pharmacology, 2010
exaly  

Erlotinib

American Journal of Cancer, 2005
openaire   +1 more source

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

Annals of Oncology, 2013
exaly  

Erlotinib

Reactions Weekly, 2016
openaire   +1 more source